IL10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via cross talk between the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways

J Shi^{1,2}, H Wang^{1,2}, H Guan^{1,2}, S Shi^{1,2}, Y Li¹, X Wu¹, N Li¹, C Yang¹, X Bai¹, W Cai¹, F Yang¹, X Wang¹, L Su¹, Z Zheng^{*1} and D Hu^{*1}

Hypertrophic scar (HS) is a serious skin fibrotic disease characterized by excessive hypercellularity and extracellular matrix (ECM) component deposition. Autophagy is a tightly regulated physiological process essential for cellular maintenance, differentiation, development, and homeostasis. Previous studies show that IL10 has potential therapeutic benefits in terms of preventing and reducing HS formation. However, no studies have examined IL10-mediated autophagy during the pathological process of HS formation. Here, we examined the effect of IL10 on starvation-induced autophagy and investigated the molecular mechanism underlying IL10-mediated inhibition of autophagy in HS-derived fibroblasts (HSFs) under starvation conditions. Immunostaining and PCR analysis revealed that a specific component of the IL10 receptor, IL10 α -chain (IL10R α), is expressed in HSFs. Transmission electron microscopy and western blot analysis revealed that IL10 inhibited starvation-induced autophagy and induced the expression of p-AKT and p-STAT3 in HSFs in a dose-dependent manner. Blocking IL10R, p-AKT, p-mTOR, and p-STAT3 using specific inhibitors (IL10RB, LY294002, rapamycin, and cryptotanshinone, respectively) showed that IL10 inhibited autophagy via IL10R α -mediated activation of STAT3 (the IL10R-STAT3 pathway) and by directly activating the AKT-mTOR pathway. Notably, these results suggest that IL10-mediated inhibition of autophagy is facilitated by the cross talk between STAT3, AKT, and mTOR; in other words, the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways. Finally, the results also indicate that mTOR-p70S6K is the molecule upon which these two pathways converge to induce IL10-mediated inhibition of autophagy in starved HSFs. In summary, the findings reported herein shed light on the molecular mechanism underlying IL10-mediated inhibition of autophagy and suggest that IL10 is a potential therapeutic agent for the treatment of HS.

Cell Death and Disease (2016) 7, e2133; doi:10.1038/cddis.2016.44; published online 10 March 2016

Autophagy is a degradative process in eukaryotic cells that removes or turns over bulk cytoplasmic constituents through the endosomal and lysosomal fusion system (i.e., autophagosomes).^{1,2} Autophagy is induced by stressful conditions such as starvation and pathogenic invasion.²

Hypertrophic scar (HS) is a major skin fibrotic disorder caused by hypercellularity and extracellular matrix (ECM) component deposition.^{3–5} HS formation is usually recognized as the consequence of disturbed tissue repair processes and/or disrupted homeostasis in the skin after traumatic injury: HS negatively impacts on patient appearance, skeletal muscle function, and quality of life in general.^{6–9} About 40–70% of surgeries and over 91% of burn injuries result in HS.¹⁰ A key feature of HS is a metabolic disorder of collagen-based ECM proteins.^{11–13} Autophagy has an important role in homeostasis of tissue structure and function.^{2,14,15} Skin autophagic

capability is associated with HS and with the pathogenesis of many human diseases.^{16–23}

Existing studies suggest that cytokines are important regulators of the autophagic process in both immune and non-immune cells.^{24–26} Interleukin-10 (IL10), expressed by a variety of mammalian cell types, was first described as a cytokine-synthesis-inhibitory factor with immunosuppressive and anti-inflammatory functions.^{27,28} IL10 has a pivotal role in wound healing^{29,30} and is a promising therapeutic agent for scar improvement in both animal models and human cutaneous wounds.^{9,31,32}

Fibroblasts are one of the most important effector cells responsible for HS formation.^{12,33,34} Thus, we were prompted to elucidate the mechanisms underlying the interactions among IL10, autophagy, and HS formation, with the aim of providing a molecular foundation for the therapeutic efficacy

¹Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, 127 West Chang-le Road, Xi'an 710032, China

*Corresponding author: Z Zheng or D Hu, Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, 127 West Chang-le Road, Xi'an 710032, China. Tel: +86 29 8477 5298; Fax: +86 29 8325 1734; E-mail: jihongshi@fmmu.edu.cn

²These authors contributed equally to this work.

Abbreviations: AKT, protein kinase B; BCA, bicinchoninic acid; DAB, diaminobenzidine; DAPI, 4',6'-diamidino-2-phenylindole; ECL, enhanced chemiluminescence; ECM, extracellular matrix; FCS, fetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HRP, horseradish peroxidase; HS, hypertrophic scar; HSFs, hypertrophic scar derived fibroblasts; IL10, interleukin 10; IL10R, receptor of interleukin 10; IL10R α , receptor of interleukin 10 α -chain; IL10R β , receptor of interleukin 10 β -chain; IL10RB, function-blocking antibody against the receptor of interleukin 10 α -chain; IgG, immunoglobulin G; mAb, monoclonal antibody; LC3, microtubule-associated protein 1 light chain 3; mTOR, mechanistic target of rapamycin; NS, normal skin; NSF, normal skin-derived fibroblasts; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PI3K, phosphoinositide 3-kinase; p70S6K, P70S6 kinase; qRT-PCR, quantitative real-time polymerase chain reaction; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; S.E.M., standard error of the mean; STAT3, signal transducers and activators of transcription 3; TBST, tris-buffered saline/0.5% tween-20

Received 27.8.15; revised 29.1.16; accepted 02.2.16; Edited by GM Fimia

Figure 1 IL10-mediated inhibition of starvation-induced autophagy in HSFs. HSFs (70–80% confluent) were starved by culturing in serum-depleted medium for 12–16 h prior to exposure to different doses of IL10 for 6 h. (a) The amount of LC3 mRNA was analyzed by qRT-PCR (data are expressed as the mean $\pm$ S.E.M.; $n = 3$; * $P < 0.05$ versus the non-starvation group; # $P < 0.05$ versus the starvation group). (b) LC3-I and LC3-II protein expression was analyzed by western blotting and the LC3-II/LC3-I ratio calculated based on signal intensity ($n = 3$; * $P < 0.05$ versus the non-starvation group; # $P < 0.05$ versus the starvation group; $\Delta P < 0.05$). (c) Few autophagosomes were observed in the non-starvation group (upper row, green arrows indicate lysosomes). Autophagosome numbers in the starved group (middle row, red arrows) increased, whereas they decreased in cells treated with 20 ng/ml IL10 (lower row). Scale bars, 2 and 0.5 μ m

IL10. We used HS tissue, HS-derived fibroblasts (HSFs), and starvation-induced autophagy in HSFs as our research platform.

Here, we report that IL10 inhibited autophagy by interfering with IL10R-mediated activation of IL10R-STAT3, as well as by activating the AKT-mTOR pathway. In addition, cross talk among STAT3, AKT, and mTOR and between the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways collaboratively regulated starvation-induced autophagy in HSFs.

Results

IL10 inhibits starvation-induced autophagy in HSFs. To test whether IL10 affects autophagy in HSFs, we subjected the cells to serum starvation in the absence or presence of IL10. Expression of the autophagy marker, LC3, in HSFs was then examined by qRT-PCR. As shown in Figure 1a, LC3 expression was upregulated by about twofold in starved HSFs ($P = 0.00014$; Figure 1a) in comparison with non-starved controls. Interestingly, LC3 expression in starved HSFs was downregulated by IL10 at concentrations as low as 5 ng/ml ($P = 0.00096$); such downregulation was more pronounced at higher concentrations (10, 20, and 40 ng/ml; $P = 0.00001$, $P = 0.00001$, and $P = 0.00001$, respectively; Figure 1a). It is noteworthy that IL10's inhibitory effect on LC3 expression reached a plateau at 10 ng/ml. Western blot analysis of LC3 isoforms (LC3-I and LC3-II) indicated that the LC3-II/LC3-I ratio was markedly higher in starved HSFs than in non-starved controls ($P = 0.00000$; Figure 1b). Intriguingly, the LC3-II/LC3-I ratio was similar to Figure 1a in the presence

of IL10 at 10 ng/ml ($P = 0.18450$), but was downregulated by higher concentrations of IL10 ($P = 0.00005$, $P = 0.00003$, and $P = 0.00001$, respectively; Figure 1b). Likewise, the LC3-II/LC3-I ratio was comparable at the three higher concentrations of IL10. These results show that IL10 inhibits expression of the autophagy molecular marker LC3 in starved HSFs.

To verify the effect of IL10 on autophagy in starved HSFs, we examined autophagosome formation using transmission electron microscopy. Ultra-structure analysis showed that the number of autophagosomes in starved HSFs was substantially higher (Figure 1c, middle row, red arrows) than that in non-starved controls (Figure 1c, upper row). Although the number of autophagosomes in starved HSFs treated with 20 ng/ml IL10 (Figure 1c, lower row; green arrow indicates a lysosome) was much lower than that in starved HSFs, it was still higher than that in the control. These results indicate that starvation induces the formation of autophagosomes in HSFs, and the process is inhibited by IL10.

IL10R α expression in HS tissues and HSFs. Immunostaining of IL10R α -chain (IL10R α) showed that, in HS and HSFs, IL10R α was localized both on the cell surface and in the cytoplasm (Figures 2a and b), a distribution and localization similar to that in normal skin (NS) and normal skin-derived fibroblasts (NSFs; Figures 2a and b).

PCR analysis of the IL10R α gene amplified a fragment of 1736 bp from both HSFs and NSFs (Figure 2c). Sequence analysis verified that both amplified fragments were derived from human IL10R α (NM-001558.3, data not shown). As expected, western blotting detected the expression of a 63 kDa IL10R α protein at similar levels in both HSFs and NSFs

($P=0.25480$; Figure 2d), as well as in HS and NS (data not shown).

IL10-mediates activation of AKT and STAT3 in starved HSFs. IL10 activates the IL10R-STAT3 signaling pathway by binding to IL10 receptors (IL10R) on the cell surface.^{11,35,36} To determine whether IL10 inhibits autophagy in HSFs via the IL10R-STAT3 signaling pathway, the expression of p-STAT3 and STAT3 was analyzed in starved HSFs in the absence or presence of different concentrations

of IL10 (Figure 3). Western blot analysis revealed that starvation downregulated p-STAT3 expression ($P=0.00020$; Figure 3a), and that IL10 alleviated the inhibitory effect of starvation on p-STAT3. By contrast, STAT3 expression appeared unaffected by either starvation or IL10 (Figure 3a). Interestingly, the antagonistic role of IL10 on starvation-mediated inhibition of p-STAT3 expression was dose-dependent ($P=0.02531$, $P=0.001392$, $P=0.00114$, and $P=0.00004$; Figure 3a), and dose-dependently increased ($\Delta P<0.05$; Figure 3a).

The AKT-mTOR pathway is essential for fundamental cellular function.^{37–39} Next, we examined whether the AKT-mTOR pathway is involved in IL10-mediated inhibition of autophagy in HSFs. Western blot analysis of AKT and p-AKT expression revealed that starvation and IL10 had similar effects ($P=0.00002$, $P=0.06549$, $P=0.01574$, $P=0.01237$, and $P=0.00006$; Figure 3b). Taken together, these results indicate that IL10 inhibits autophagy via both the IL10R-STAT3 and AKT-mTOR pathways.

IL10 inhibits autophagy via the IL10/IL10R-STAT3 pathway. To verify involvement of the IL10R-STAT3 pathway in IL10-mediated inhibition of autophagy in starved HSFs, the expression of p-STAT3/STAT3, p-AKT/AKT, and LC3-II/LC3-I in starved HSFs was compared in the presence/absence of IL10 and in the presence/absence of an anti-IL10R antibody (IL10RB). As shown in Figure 4, IL10RB reversed IL10-mediated effects on the expression of p-STAT3 ($P=0.04779$, Figure 4a) and p-AKT ($P=0.00011$, Figure 4b) and on the ratio of LC3-II/LC3-I ($P=0.00262$, Figure 4c) in starved HSFs. These results indicate that IL10-mediated inhibition of autophagy in starved HSFs is at least partially IL10R-dependent.

To further understand the signal transduction pathway via which IL10 inhibits autophagy in starved HSFs, cryptotanshinone (a specific p-STAT3 inhibitor) was applied to starved HSFs in the presence/absence of IL10. Western blot analysis of p-STAT3/STAT3, p-AKT/AKT, LC3-II/LC3-I, and p-mTOR/mTOR showed that cryptotanshinone substantially suppressed IL10-induced p-STAT3 expression ($P=0.00022$, Figure 4d), and (albeit to a lesser extent) that of IL10-induced p-AKT expression ($P=0.00026$, Figure 4e), despite the presence of IL10; however, p-mTOR expression was unchanged ($P=0.13835$; Figure 4f). Nonetheless, cryptotanshinone did not significantly alter the LC3-II/LC3-I ratio, which was reduced in the presence of IL10 ($P=0.58288$; Figure 4g). These results suggest that IL10-mediated inhibition of autophagy in starved HSFs involves p-STAT3/STAT3, p-AKT/AKT, and p-mTOR/mTOR, probably via the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways.

IL10 inhibits autophagy via the IL10-AKT-mTOR pathway. To examine the role of the IL10-AKT-mTOR pathway in IL10-mediated inhibition of autophagy in starved HSFs, LY294002 (a specific inhibitor of p-AKT) was applied to starved HSFs in the presence/absence of IL10. Western blot analysis of p-AKT/AKT, p-STAT3/STAT3, and LC3-II/LC3-I ratios showed that LY294002 suppressed IL10-induced p-AKT expression ($P=0.00007$; Figure 5a) and, to a lesser extent, downregulated IL10-induced p-STAT3 expression ($P=0.00715$; Figure 5b); it also covered IL10-mediated reduction in the LC3-II/LC3-I ratio ($P=0.01716$; Figure 5c).

To examine the involvement of p-mTOR in IL10-mediated inhibition of autophagy in starved HSFs, rapamycin (a specific mTOR inhibitor) was applied to starved HSFs in the presence or absence of IL10. Western blot analysis of p-mTOR/mTOR, p-AKT/AKT, p-STAT3/STAT3, and LC3-II/LC3-I ratios showed that rapamycin suppressed IL10-mediated upregulation of p-mTOR ($P=0.00034$; Figure 5d), p-AKT ($P=0.04379$; Figure 5e), and p-STAT3 ($P=0.00444$; Figure 5f) expression.

However, rapamycin significantly increased the LC3-II/LC3-I ratio ($P=0.00228$; Figure 5g). These results imply that p-mTOR is a key and signaling molecule involved in IL10-mediated inhibition of autophagy in starved HSFs because inhibiting p-mTOR affects both the AKT-mTOR and IL10R-STAT3 pathways.

IL10 inhibits autophagy via cross talk between the AKT-mTOR and IL10R-STAT3 pathways. The involvement of both the AKT-mTOR and IL10R-STAT3 pathways in IL10-mediated inhibition of starvation-induced autophagy in HSFs led us to hypothesize that these two pathways interact to facilitate IL10-mediated inhibition of autophagy. To test this, starved HSFs were treated with LY294002/rapamycin or with cryptotanshinone/rapamycin in the presence/absence of IL10. Western blot analysis of p-AKT/AKT, p-STAT3/STAT3, p-mTOR/mTOR, and LC3-II/LC3-I showed that, as expected, LY294002/cryptotanshinone almost completely abolished p-AKT ($P=0.11713$ and $P=0.00000$; Figure 6a) and p-STAT3 ($P=0.00000$ and $P=0.00002$; Figure 6b), even if in the presence of IL10. Whereas LY294002 alone significantly suppressed IL10-mediated upregulation of p-AKT expression, cryptotanshinone alone failed to suppress starvation-induced or IL10-mediated p-AKT expression in starved HSFs independent of IL10 (Figure 6a). By contrast, LY294002 alone had no significant effect on p-STAT3 expression in the presence or absence of IL10, whereas cryptotanshinone strongly suppressed p-STAT3 expression in starved HSFs independently of IL10 (Figure 6b). More interestingly, LY294002 alone downregulated p-mTOR expression in a manner similar to p-AKT (Figures 6a and c), whereas cryptotanshinone upregulated starvation-induced p-mTOR expression in the absence of IL10 ($P=0.00509$; Figure 6c). In the absence of IL10, both LY294002 and cryptotanshinone (either alone or together) failed to increase the LC3-II/LC3-I ratio ($P=0.12734$; Figure 6d), whereas in the presence of IL10, cryptotanshinone (either alone or together with LY294002) further reduced the LC3-II/LC3-I ratio ($P=0.00840$; Figure 6d).

The combination of cryptotanshinone and rapamycin strongly suppressed expression of p-AKT ($P=0.00006$ and $P=0.00004$; Figure 6e), p-STAT3 ($P=0.00009$ and $P=0.33470$; Figure 6f), and p-mTOR ($P=0.00045$ and $P=0.00125$; Figure 6g), and abolished LC3-I expression while at the same time markedly increasing LC3-II expression, resulting in a striking increase in the LC3-II/LC3-I ratio ($P=0.00074$ and $P=0.00064$; Figure 6h) in starved HSFs. Similar to the observations described in Figure 6a, cryptotanshinone alone alleviated starvation-induced suppression of p-AKT expression in the presence or absence of IL10 (Figure 6e), as did rapamycin (Figure 6e).

Furthermore, consistent with the observations in Figure 6b, cryptotanshinone alone strongly inhibited p-STAT3 expression, even in the presence of IL10 ($P=0.35483$; Figure 6f). By contrast, rapamycin alone slightly reversed starvation-induced suppression of p-STAT3 expression (Figure 6f). Cryptotanshinone, either alone or together with rapamycin, either abolished or strongly inhibited p-mTOR expression in the absence of IL10 ($P=0.00783$; Figure 6g). Cryptotanshinone alone did not affect IL10-mediated rescue of starvation-induced p-mTOR inhibition, whereas it inhibited IL10-mediated rescue of p-mTOR

expression when combined with rapamycin in the presence of IL10. Rapamycin alone blocked IL10-mediated rescue of starvation-induced p-mTOR inhibition (Figure 6g). These

results further indicate the involvement of both the AKT-mTOR and IL10R-STAT3 pathways in IL10-mediated inhibition of autophagy in starved HSFs.

Figure 4 IL10-mediated inhibition of autophagy via the IL10/IL10R-STAT3 pathway. HSFs (70–80% confluent) were starved by culturing in serum-depleted medium for 12–16 h. p-STAT3 and p-AKT protein expression in response to IL10 treatment was then assessed after incubation with IL10RB for 30 min. (a) p-STAT3 and STAT3 protein expression and changes in the p-STAT3/STAT3 ratio in the presence of IL10 and/or IL10RB (data are expressed as the mean $\pm$ S.E.M.; $n=3$; $^*P<0.05$ versus the starvation control and $^{\#}P<0.01$ versus the IL10RB treatment group). (b) p-AKT and AKT protein expression and changes in the p-AKT/AKT ratio in the presence of IL10 and/or IL10RB ($n=3$; $^*P<0.01$ versus the starvation control and $^{\#}P<0.01$ versus the IL10RB treatment group). (c) LC3-I and LC3-II protein expression and changes in the LC3-II/LC3-I ratio in the presence of IL10 and/or IL10RB ($n=3$; $^*P<0.05$ versus the starvation control; $^{\Delta}P>0.05$ versus the starvation group; $^{\#}P<0.01$ versus the IL10RB treatment group). (d) p-STAT3 and STAT3 protein expression and changes in the p-STAT3/STAT3 ratio in the presence of IL10 and/or the STAT3 inhibitor, cryptotanshinone ($n=3$; $^*P<0.001$ versus the starvation control; $^{\#}P<0.01$ versus the starvation group; $^{\Delta}P>0.05$ versus the cryptotanshinone-treatment group). (e) p-AKT and AKT protein expression and changes in the p-AKT/AKT ratio in the presence of IL10 and/or cryptotanshinone ($n=3$; $^*P<0.001$ versus the starvation control or the cryptotanshinone-treated group). (f) p-mTOR and mTOR protein expression and changes in the p-mTOR/mTOR ratio in the presence of IL10 and/or cryptotanshinone ($n=3$; $^{\Delta}P>0.05$ versus the starvation control or cryptotanshinone-treated groups and $^{\#}P<0.01$ versus the starvation control group). (g) LC3-I and LC3-II protein expression and changes in the LC3-II/LC3-I ratio in the presence of IL10 and/or cryptotanshinone ($n=3$; $^{\Delta}P>0.05$ versus the starvation control or cryptotanshinone-treated groups and $^*P<0.05$ versus the starvation control group).

IL10 inhibits autophagy via the mTOR-p70S6K pathway. Phosphorylated p70S6K (p-p70S6K) is a signaling molecule that acts downstream of mTOR. As shown in Figures 7a and

b, starvation inhibited the expression of both p-mTOR and p-p70S6K; however, IL10 rescued the expression of p-mTOR ($P=0.16128$, $P=0.03496$, $P=0.00086$, and $P=0.00009$;

Figure 5 IL10-mediated inhibition of autophagy via the IL10/AKT-mTOR pathway. HSFs (70–80% confluent) were starved by culturing in serum-depleted medium for 12–16 h. p-AKT, p-STAT3, and p-mTOR protein expression in response to IL10 was assessed after incubation with LY294002 or rapamycin for 30 min. (a) p-AKT and AKT protein expression and changes in the p-AKT/AKT ratio in the presence of IL10 and/or the p-AKT inhibitor LY294002 (data are expressed as the mean $\pm$ S.E.M.; $n=3$; ** $P<0.001$ versus the starvation control and * $P<0.05$ versus the LY294002 treatment group). (b) p-STAT3 and STAT3 protein expression and changes in the p-STAT3/STAT3 ratio in the presence of IL10 and/or LY294002 ($n=3$; $\Delta P>0.05$ versus the starvation and LY294002 treatment groups). (c) LC3-I and LC3-II protein expression and changes in the LC3-II/LC3-I ratio in the presence of IL10 and/or LY294002 ($n=3$; $\Delta P>0.05$ versus the starvation group; ** $P<0.001$ versus the LY294002 treatment group). (d) p-mTOR and mTOR protein expression and changes in the p-mTOR/mTOR ratio in the presence of IL10 and/or the p-mTOR inhibitor, rapamycin (data are expressed as the mean $\pm$ S.E.M.; $n=3$; $\Delta P>0.05$ versus the starvation and rapamycin-treatment groups). (e) p-AKT and AKT protein expression and changes in the p-AKT/AKT ratio in the presence of IL10 and/or rapamycin ($n=3$; $\Delta P>0.05$ versus the starvation and rapamycin-treatment groups). (f) p-STAT3 and STAT3 protein expression and changes in the p-STAT3/STAT3 ratio in the presence of IL10 and/or rapamycin ($n=3$; $\Delta P>0.05$ versus the starvation and rapamycin-treatment groups). (g) LC3-I and LC3-II protein expression and changes in the LC3-II/LC3-I ratio in the presence of IL10 and/or rapamycin ($n=3$; * $P<0.01$ versus the starvation group and ** $P<0.001$ versus the rapamycin-treatment group)

Figure 6 IL10-mediated inhibition of autophagy via cross talk between the AKT-mTOR and IL10R-STAT3 pathways. HSFs (70–80% confluent) were starved by culturing in serum-depleted medium for 12–16 h. p-AKT, p-STAT3, and p-mTOR protein expression in response to IL10 was then assessed after treatment with LY294002, cryptotanshinone, and rapamycin (or combinations thereof) for 30 min. (a) p-AKT and AKT protein expression and changes in the p-AKT/AKT ratio in the presence of IL10, LY294002, or cryptotanshinone (or combinations thereof) (data are expressed as the mean $\pm$ S.E.M.; $n = 3$; $\Delta P > 0.05$ and $**P < 0.001$ versus individual treatment groups; $\Delta P > 0.05$ and $**P < 0.001$ versus the LY294002+cryptotanshinone or cryptotanshinone-treatment groups, and $\Delta P > 0.05$ versus the LY294002 treatment group). (b) p-STAT3 and STAT3 protein expression and changes in the p-STAT3/STAT3 ratio in the presence of IL10, LY294002, or cryptotanshinone (or combinations thereof) ($n = 3$; $**P < 0.001$ versus individual treatment groups and $\Delta P > 0.05$ and $**P < 0.001$ versus the LY294002+cryptotanshinone or individual treatment groups). (c) p-mTOR and mTOR protein expression and changes in the p-mTOR/mTOR ratio in the presence of IL10, LY294002, or cryptotanshinone (or combinations thereof) ($n = 3$; $\Delta P > 0.05$ versus the LY294002-treated or LY294002+cryptotanshinone-treated groups; $\Delta P > 0.05$ versus the cryptotanshinone-treated group and $**P < 0.001$ versus the LY294002-treated group). (d) LC3-I and LC3-II protein expression and changes in the LC3-II/LC3-I ratio in the presence of IL10, LY294002, or cryptotanshinone (or combinations thereof) ($n = 3$; $\Delta P > 0.05$ versus the cryptotanshinone- or LY294002-treated groups; $**P < 0.001$ versus the group LY294002-treated group; and $*P < 0.01$ versus the LY294002+cryptotanshinone-treated group). (e) p-AKT and AKT protein expression and changes in the p-AKT/AKT ratio in the presence of IL10, cryptotanshinone, or rapamycin (or combinations thereof) ($n = 3$; $**P < 0.001$ and $*P < 0.01$ versus the individual treatment groups; $*P < 0.05$ versus the cryptotanshinone+rapamycin-treated group). (f) p-STAT3 and STAT3 protein expression and changes in the p-STAT3/STAT3 ratio in the presence of IL10, cryptotanshinone, or rapamycin (or combinations thereof) ($n = 3$; $**P < 0.001$ versus the rapamycin-treated group; $\Delta P > 0.05$ versus the cryptotanshinone+rapamycin-treated group). (g) p-mTOR and mTOR protein expression and changes in the p-mTOR/mTOR ratio in the presence of IL10, cryptotanshinone, or rapamycin (or combinations thereof) ($n = 3$; $**P < 0.001$ and $*P < 0.01$ versus the individual treatment groups or the cryptotanshinone+rapamycin-treated group). (h) LC3-I and LC3-II protein expression and changes in the LC3-II/LC3-I ratio in the presence of IL10, cryptotanshinone, or rapamycin (or combinations thereof) ($n = 3$; $**P < 0.001$ versus the starvation control and individual treatment groups; $*P < 0.01$ versus the cryptotanshinone+rapamycin-treated or individual treatment groups; and $\Delta P > 0.05$ versus the cryptotanshinone+rapamycin-treated group)

Figure 7 IL10-mediated inhibition of autophagy via the mTOR-p70S6K pathway. HSFs (70–80% confluent) were starved by culture in serum-depleted medium for 12–16 h. p-mTOR and p-p70S6K protein expression in response to IL10 treatment was then assessed in the presence or absence of rapamycin for 30 min. (a) p-mTOR and mTOR protein expression and changes in the p-mTOR/mTOR ratio in the presence of IL10 (data are expressed as the mean $\pm$ S.E.M.; $n=3$, * $P<0.05$ versus the non-starvation group and $^{\#}P<0.05$ versus the starvation group; $^{\Delta}P<0.05$). (b) p-p70S6K and p70S6K protein expression and changes in the p-p70S6K/p70S6K ratio in the presence of IL10 ($n=3$; * $P<0.05$ versus the non-starvation group and $^{\#}P<0.05$ versus the starvation group; $^{\Delta}P<0.05$). (c) p-p70S6K and p70S6K protein expression and changes in the p-p70S6K/p70S6K ratio in the presence of IL10 and/or rapamycin ($n=3$; ** $P<0.001$ versus the non-starvation control and ** $P<0.001$ versus the starvation group; $^{\Delta}P>0.05$ versus the rapamycin-treatment group)

Figures 7a) and p-p70S6K ($P=0.00023$, $P=0.00006$, $P=0.00000$, and $P=0.00016$; Figure 7b) from starvation-induced inhibition in HSFs in a dose-dependent manner. Rapamycin strongly inhibited p-p70S6K expression ($P=0.00007$; Figure 7c), even in the presence of IL10 ($P=0.00079$; Figure 7c), but this effect was irreversible in the presence of IL10 ($P=0.23409$; Figure 7c). This result indicates that p-mTOR likely acts as a signaling molecule on which upstream signals converge before being transmitted downward to p-p70S6K.

Discussion

HS formation usually results from disturbance of the tightly controlled tissue repair mechanism due to traumatic skin injury.^{8,12} HS is not only aesthetically displeasing, but also obstructs normal muscle function, thereby contributing to psychological and physical suffering.^{6–9}

Autophagy is a lysosomal degradation pathway essential for cellular survival, differentiation, development, and homeostasis.^{17,40–42} During disease pathogenesis, autophagy principally serves an adaptive role to protect organisms from pathogen infection and from aging, neurodegeneration, and cancer.^{16,18–22} LC3 is an indicator of autophagy induction in mammals. LC3 typically localizes in the cytosol under normal conditions and translocates to autophagosomal membranes when autophagy is induced.^{43,44} There are two forms of LC3: LC3-I and LC3-II. LC3-I is the non-lipidated form, with a molecular weight of 18 kDa, and LC3-II is the lipidated form, with a molecular weight of 16 kDa.^{45,46} Conversion of LC3-I to LC3-II correlates with the formation of autophagosomes.^{43,44,47} Thus, changes in the LC3-II/LC3-I ratio are indicative of autophagic activity.

Currently, there is no effective therapy for HS, largely because the mechanisms underlying HS development are poorly understood.^{10,48} IL10 was identified as a promising therapeutic agent that can reduce HS.^{31,32} To clearly elucidate the mechanisms underlying the effects of IL10 on autophagy and HS formation, we examined autophagy in HSFs and NSF

in the presence or absence of IL10. The results showed that starvation can induce autophagic protein (Supplementary Figure 1) and mRNA (Supplementary Figure 2) expression in both HSFs and NSF, and that this can be inhibited by IL10. As expected, the difference was more noticeable in HSFs than in NSF (Supplementary Figures 1 and 2). The results also suggest (albeit indirectly) that IL10 has potential therapeutic benefit for the prevention and reduction of HS formation. Thus, we used HS tissue and serum-starved HSFs as our research platform.

IL10 is thought to function via the STAT3-mediated signaling pathway.^{11,35,36} Specifically, dimerized IL10 binds to the IL10R complex, which comprises two IL10R α -chains (IL10R α) and two accessory IL10R β -chains (IL10R β). IL10R α is unique to IL10R, whereas IL10R β is more diverse, being involved in signaling pathways related to several cytokines, including IL-22, IL-26, an x-interferon (λ -IFN), IL-28 A/B, and IL-29.^{11,36} Therefore, preventing the inhibition of IL10R α functions would specifically disrupt IL10 functions that depend on IL10R α . STAT3 is a signaling molecule that interacts with multiple factors. STAT3 is phosphorylated by JAK1 and Tyk2, resulting in its dimerization and translocation to the nucleus to activate target gene expression.^{11,35,36,49} To date, it is unclear whether the IL10R-STAT3 pathway is the primary mediator of IL10 function.^{39,50}

The AKT-mTOR pathway is responsible for cell survival, energy metabolism, and protein synthesis.^{37,38} The results presented herein showed that IL10 increased STAT3 phosphorylation at Tyr705 and AKT phosphorylation at Ser473 (Figures 3a and b) in a dose-dependent manner. Treatment of HSFs with IL10RB inhibited p-STAT3 (Figure 4a) and p-AKT (Figure 4b) expression, whereas treatment of HSFs with the PI3K blocker, LY294002, downregulated both p-AKT (Figure 5a) and p-STAT3 (Figure 5b). These results imply that IL10 induces cross talk between the IL10R-STAT3 and AKT-mTOR pathways in starvation-treated HSFs.

To confirm whether IL10 inhibits autophagy via cross talk between the AKT-mTOR and IL10R-STAT3 pathways, HSFs were treated with various combinations of IL10,

follows: A260/A280 (1.9–2.0). The primer sets used were as follows: LC3, forward 5'-CAACATGAGCGAGTTGGTCAAGA-3' and reverse 5'-ACTCACCATGCTGTGCTGGTTC-3'; Beclin1, forward 5'-ATGCGAGGTGAGCTTCGTGTG3' and reverse 5'-CTGGGCTGTGGTAAGTAATGGA-3'; Atg5, forward 5'-GCTGCACCTTATTACCAAGCCTCTG-3' and reverse 5'-AGCGTACTCAAATGGGTCAACATTC-3'; Atg12, forward 5'-AGTAGAGCGAACACGAACCATCC-3' and reverse 5'-CCACGCCTGAGACTTGCGAGTA-3'; and GAPDH, forward 5'-GCACCGTCAAGCTGAGAAC-3' and reverse 5'-TGGTGAAGACGCCAGTGGGA-3'. The relative expression of the target gene transcripts was expressed as the mean abundance from three independent reactions. Expression was normalized against that of GAPDH.

To detect IL10R α , IL10R α was amplified by PCR using primers 5'-GCGAGA TCTATGCTGCCGTGCGCTCGTAGTGC-3' (upstream) and 5'-CAGGGTACCTCACTC ACTTGACTGCAGGCTAGAGAT-3' (downstream) (*Bgl*II and *Kpn*I restriction sites underlined). The PCR products were then cloned into the pMD18T vector (Takara, 6011) and sequenced (Sangon, Shanghai, China).

Western blot analysis. Cultured HSFs were harvested, washed in PBS, and resuspended in RIPA cell lysis solution (Beyotime; P0013C) supplemented with 200 μ g/ml phenylmethylsulfonyl fluoride (Boster, Wuhan, Hubei, China; AR1179), phosphatase inhibitor cocktail (Sigma; P0044), and protease inhibitor cocktail (Sigma; P8340). The protein concentration of the cell lysates was determined using the BCA assay (Pierce, Rockford, IL, USA; #23225).

Western blotting was performed as previously described.^{9,53} Briefly, cell lysates containing equal amounts of protein were separated in 7% (for phosphorylated products) or 14% (for LC3) SDS-PAGE gels and transferred to polyvinylidene fluoride (Millipore, Temecula, CA, USA; ISEQ00010) membranes at 100 V for 25 min (for LC3) or 100 min (for mTOR, p70S6K, STAT3, and AKT). Membranes were then blocked with 5% non-fat milk in TBST (Tris-buffered saline/0.5% Tween-20) at room temperature for 3 h, followed by incubation at 4 °C overnight with rabbit mAbs specific for IL10R α (Epitomics, Burlingame, CA, USA; GTX102731), p-STAT3 (CST, #9145), STAT3 (CST, #12640), p-AKT (CST, #4060), AKT (CST, #4691), p-mTOR (CST, #5536), mTOR (CST, #2983), p-P70S6K (CST, #9234), p70S6K (CST, #9202), or LC3B (CST, Danvers, MA, USA; #3868). Finally, the membranes were washed and incubated with HRP-conjugated secondary antibodies (1:3000 dilution; Bioss, Beijing, China; bs-0295G-HRP). The immunoreactive protein bands were detected using ECL reagents (Millipore; WBKLS0100). The signal intensity of each protein was quantified by scanning the membrane with an image analyzer (Alpha Innotech, San Leandro, CA, USA). The membrane was then stripped of antibodies and re-probed with a rabbit mAb against β -actin (1:2000 dilution; CST; #4970) as an internal loading control.

Statistical analysis. Quantitative data are expressed as the mean $\pm$ standard error of the mean (S.E.M.). Student's *t*-test was used to compare data between two groups and analysis of variance was used for multiple-group comparisons. A *P*-value of <0.05 was considered statistically significant.

Conflict of Interest

The authors declare conflict of interest.

Acknowledgements. This work was supported by the National Natural Science Foundation of China (Grant No. 81272098 and 81571914) and a 2012 Grant-in-Aid for Scientific Research from Xijing Hospital (Grant No. XJZT12D01).

- Baehrecke EH. Autophagy: dual roles in life and death? *Nat Rev Mol Cell Biol* 2005; **6**: 505–510.
- Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. *Curr Top Microbiol Immunol* 2009; **335**: 1–32.
- Sidgwick GP, Bayat A. Extracellular matrix molecules implicated in hypertrophic and keloid scarring. *J Eur Acad Dermatol Venerol* 2012; **26**: 141–152.
- Zhang ZF, Zhang YG, Hu DH, Shi JH, Liu JQ, Zhao ZT *et al*. Smad interacting protein 1 as a regulator of skin fibrosis in pathological scars. *Burns* 2011; **37**: 665–672.
- Campaner AB, Ferreira LM, Gragnani A, Bruder JM, Cusick JL, Morgan JR. Upregulation of TGF- β 1 expression may be necessary but is not sufficient for excessive scarring. *J Invest Dermatol* 2006; **126**: 1168–1176.
- Bayat A, McGrouther DA, Ferguson MW. Skin scarring. *BMJ* 2003; **326**: 88–92.
- Brown BC, McKenna SP, Siddhi K, McGrouther DA, Bayat A. The hidden cost of skin scars: quality of life after skin scarring. *J Plast Reconstr Aesthet Surg* 2008; **61**: 1049–1058.
- Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation following burns and trauma: New Approaches to Treatment. *PLoS Med* 2007; **4**: e234.
- Shi JH, Guan H, Shi S, Cai WX, Bai XZ, Hu XL *et al*. Protection against TGF- β 1-induced fibrosis effects of IL10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring. *Arch Dermatol Res* 2013; **305**: 341–352.
- Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. *Mol Med* 2011; **17**: 113–125.
- Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. *Plast Reconstr Surg* 1999; **104**: 1435–1458.
- van der Veer WM, Bloemen MC, Ulrich MM, Molema G, van Zijnen PP, Middelkoop E *et al*. Potential cellular and molecular causes of hypertrophic scar. *Burns* 2009; **35**: 15–29.
- Wolfram D, Tzankov A, Püzl P, Piza-Katzer H. Hypertrophic scars and keloids—a review of their pathophysiology, risk factors, and therapeutic management. *Dermatol Surg* 2009; **35**: 171–181.
- Tommasino C, Marconi M, Ciarlo L, Matarrese P, Malorni W. Autophagic flux and autophagosome morphogenesis require the participation of sphingolipids. *Apoptosis* 2015; **20**: 645–657.
- Chang NC, Nguyen M, Bourdon J, Risse PA, Martin J, Danilou G *et al*. Bcl-2-associated autophagy regulator Naf-1 required for maintenance of skeletal muscle. *Hum Mol Genet* 2012; **21**: 2277–2287.
- Jin S, White E. Tumor suppression by autophagy through the management of metabolic stress. *Autophagy* 2008; **4**: 563–566.
- Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell* 2008; **132**: 27–42.
- Orvadahl A, Levine B. Eating the enemy within: autophagy in infectious diseases. *Cell Death Differ* 2009; **16**: 57–69.
- Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. *Science* 2004; **306**: 990–995.
- Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease. *Biochim Biophys Acta* 2009; **1792**: 3–13.
- Winslow AR, Rubinstein DC. Autophagy in neurodegeneration and development. *Biochim Biophys Acta* 2008; **1782**: 723–729.
- Yen WL, Klionsky DJ. How to live long and prosper: autophagy, mitochondria, and aging. *Physiology* 2008; **23**: 248–262.
- Shi JH, Hu DH, Zhang ZF, Bai XZ, Wang HT, Zhu XX *et al*. Reduced expression of microtubule-associated protein 1 light chain 3 in hypertrophic scars. *Arch Dermatol Res* 2012; **304**: 209–215.
- Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. *Cell* 2004; **119**: 505–517.
- Pyo JO, Jang MH, Kwon YK, Lee HJ, Jun JI, Woo HN *et al*. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. *J Biol Chem* 2005; **280**: 20722–20729.
- Arico S, Petiot A, Bauvy C, Dubbelhuis PF, Meijer AJ, Codogno P *et al*. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. *J Biol Chem* 2001; **276**: 35243–35246.
- Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J Exp Med* 1989; **170**: 2081–2095.
- Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. *Annu Rev Immunol* 1993; **11**: 165–190.
- Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med* 1999; **341**: 738–746.
- Peranteau WH, Zhang L, Muvarak N, Badillo AT, Radu A, Zoltick PW *et al*. IL10 overexpression decrease inflammatory mediators and promotes regenerative healing in an adult model of scar formation. *J Invest Dermatol* 2008; **128**: 1852–1860.
- Occleston NL, O'Kane S, Goldspink N, Ferguson MW. New therapeutics for the prevention and reduction of scarring. *Drug Discovery Today* 2008; **13**: 973–981.
- Kieran I, Knock A, Bush J, So K, Metcalfe A, Hobson R *et al*. Interleukin-10 reduces scar formation in both animal and human cutaneous wounds: results of two preclinical and phase II randomized control studies. *Wound Repair Regen* 2013; **21**: 428–436.
- Hinz B. Formation and function of the myofibroblast during tissue repair. *J Invest Dermatol* 2007; **127**: 526–537.
- Hinz B. The myofibroblast: paradigm for a mechanically active cell. *J Biomech* 2010; **43**: 146–155.
- Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K *et al*. Biology of interleukin-10. *Cytokine Growth Factor Rev* 2010; **21**: 331–344.
- Glockner EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL10 and IL10 receptor defects in humans. *Ann N Y Acad Sci* 2011; **1246**: 102–107.
- Franke TF, Kaplan DR, Cantley LC. p13K: downstream AKTion block apoptosis. *Cell* 1997; **88**: 435–437.
- Franke TF. Intracellular signaling by AKT: bound to be specific. *Sci Signal* 2008; **1**: pe29.
- Park HJ, Lee SJ, Kim SH, Han J, Bae J, Kim SJ *et al*. IL10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway. *Mol Immunol* 2011; **48**: 720–727.
- Meijer AJ, Dubbelhuis PF. Amino acid signaling and the integration of metabolism. *Biochem Biophys Res Commun* 2004; **313**: 397–403.
- Riddle DL, Gorski SM. Shaping and stretching life by autophagy. *Dev Cell* 2003; **5**: 364–365.

42. Yoshimori T. Autophagy: a regulated bulk degradation process inside cells. *Biochem Biophys Res Commun* 2004; **313**: 453–458.
43. Asanuma K, Tanida I, Shirato I, Ueno T, Takahara H, Nishitani T *et al*. MAP-LC3 a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. *FASEB J* 2003; **17**: 1165–1167.
44. Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. *Autophagy* 2005; **1**: 84–91.
45. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T *et al*. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J* 2000; **19**: 5720–5728.
46. Tanida I, Nishitani T, Nemoto T, Ueno T, Kominami E. Mammalian Apg12p, but not the Apg12p-Apg5p conjugate, facilitates LC3 processing. *Biochem Biophys Res Commun* 2002; **296**: 1164–1170.
47. Karim MR, Kanazawa T, Daigaku Y, Fujimura S, Miotto G, Kadowaki M. Cytosolic LC3 ratio as a sensitive index of macroautophagy in isolated rat hepatocytes and H4-II-E cells. *Autophagy* 2007; **3**: 553–560.
48. Saito M, Yamazaki M, Maeda T, Matsumura H, Setoguchi Y, Tsuboi R. Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction. *Arch Dermatol Res* 2012; **304**: 217–222.
49. Donnelly RP, Dickensheets H, Finbloom DS. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. *J Interferon Cytokine Res* 1999; **19**: 563–573.
50. Agbanoma G, Li C, Ennis D, Palfreeman AC, Williams LM, Brennan FM. Production of TNF- α in macrophages activated by T cells, compared with lipopolysaccharide, uses distinct IL10-dependent regulatory mechanism. *J Immunol* 2012; **188**: 1307–1317.
51. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. *FEBS Lett* 2010; **584**: 1287–1295.
52. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. *Ann Rev Immunol* 1996; **14**: 483–510.
53. Hu X, Wang H, Liu J, Fang X, Tao K, Wang Y *et al*. The role of ERK and JNK signaling in connective tissue growth factor induced extracellular matrix protein production and scar formation. *Arch Dermatol Res* 2013; **305**: 433–445.

Cell Death and Disease is an open-access journal published by **Nature Publishing Group**. This work is licensed under a **Creative Commons Attribution 4.0 International License**. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies this paper on Cell Death and Disease website (<http://www.nature.com/cddis>)